💊
Carmustine medac (previously Carmustine Obvius)
carmustine
Enfermedad de Hodgkin; Linfoma no Hodgkin
✅ Autorizado
Genérico
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma).
⚠️ Seguridad del paciente
No
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac